Case reportPublished 26 Mar 2018
Utilizing UL97 Resistant Codon Specificities to Guide Pharmacotherapy Treatment Decisions in Resistant Cytomegalovirus Infections
1Department of Transplant Surgery, Vidant Medical Center, Greenville, NC, USA; 2Department of Transplant Surgery, East Carolina University, Greenville, NC, USA; 3Department of Pharmacy, Vidant Medical Center, Greenville, NC, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The development of cytomegalovirus (CMV) drug resistance has become an emerging clinical challenge. In kidney transplant recipients (KTR), CMV infection is a risk factor for acute rejection, has a detrimental effect on patient survival, and predisposes patients to secondary opportunistic infections. We report here the case of a kidney transplant patient on valganciclovir prophylaxis who developed recurrent CMV infections, complicated by UL97 ganciclovir (GCV) resistance. Our patient underwent unsuccessful treatment courses with high dose GCV, foscarnet and cidofovir. Compassionate use maribavir was initiated and resulted in full recovery. Through this case report and literature review, we highlight potential strategies for the successful management of CMV resistance.
Subjects
SurgeryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical and Experimental Transplantation
- SubjectSurgery
- BylineArticles whose byline prints “Angela Q Maldonado”
- BylineArticles whose byline prints “David B Leeser”
- BylineArticles whose byline prints “Tomefa E Asempa”